Category: Company News
-

Global Engine Group Advances Space-to-AI Edge Infrastructure Platform With Angkasa-X Collaboration
The agreement moves Global Engine Group beyond its May memorandum of understanding toward a Sarawak proof-of-concept combining satellite ground stations, edge data center infrastructure and local AI data processing. Key Investor Takeaways Why GLE Stock Is in Focus Global Engine Group is moving its proposed collaboration with Angkasa-X into a more defined development phase as…
-

Fort Technology Signs Logia USA Acquisition Deal to Enter Data Center Fuel Integrity Market
The proposed acquisition gives Fort Technology a 50.1% controlling stake in an early-stage U.S. fuel integrity business, backed by a milestone-based $2 million credit facility and a structure that could materially reduce Fort’s ownership if Logia USA reaches higher sales thresholds. Key Investor Takeaways Why FRTT Stock Is in Focus Fort Technology’s Logia USA acquisition…
-

Neuronetics Narrows Q2 Loss as Greenbrook Growth Drives 9% Revenue Increase
Neuronetics improved margins, reached positive adjusted EBITDA and lowered its 2026 operating expense outlook, although NeuroStar revenue declined during the quarter. Key Investor Takeaways Why STIM Stock Is in Focus Neuronetics’ Q2 loss narrowed substantially as growth at its Greenbrook clinics, margin expansion and lower expenses moved the company closer to profitability. Total revenue increased…
-

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances
The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat’s planned Phase 3 study. Key Investor Takeaways Why MREO Stock Is in Focus Mereo BioPharma’s updated cash runway into late 2027 gives the clinical-stage company additional operating visibility while…
-

Senmiao Technology Targets 100 MW Initial Digital Infrastructure Development Through Energence Utah Partnership
The proposed $5 million staged investment would give Senmiao an initial position in a Utah infrastructure campus targeting 100 MW of firm capacity by Year 2 and potentially up to 1.2 GW by Year 6. Key Investor Takeaways Why AIHS Stock Is in Focus Senmiao Technology’s proposed Energence Utah partnership represents an early move in…
-

American Fusion Appoints John Gerdin as Independent Director to Strengthen Capital Markets Strategy
John Gerdin joins American Fusion’s board and advisory team with experience in international finance and capital formation as the company advances its developmental Texatron Fusion Engine and builds its corporate infrastructure. Key Investor Takeaways Why AMFN Stock Is in Focus American Fusion (USOTC:AMFN) appointed John Gerdin to its Board of Directors as an Independent Director…
-

Premier Graphene Posts First Profitable Quarter and Targets Further Profit Growth
Premier Graphene reported its first profitable quarter in company history following the completion of commercial contracts, while management said it expects profitability to increase in the third quarter. Key Investor Takeaways Why BIEI Stock Is in Focus Premier Graphene (USOTC:BIEI) reported its first profitable quarter in corporate history, with management saying completed contracts generated sufficient…
-

La Rosa Holdings Launches Strategic Alternatives Review and Ends Consensus Core Technologies Deal
La Rosa Holdings is evaluating transactions, acquisitions, partnerships and asset divestitures after terminating its proposed Consensus Core Technologies transaction, while separately regaining compliance with Nasdaq’s periodic filing requirement. Key Investor Takeaways Why LRHC Stock Is in Focus La Rosa Holdings (NASDAQ:LRHC) has begun a comprehensive strategic alternatives review aimed at strengthening its operating platform and…
-

Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance. Key Investor Takeaways Why HRTX Stock Is in Focus Heron Therapeutics (NASDAQ:HRTX) withdrew its full-year 2026 guidance after second-quarter revenue came in below internal expectations and uncertainty…
-

Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even
Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor Takeaways Why QTRX Stock Is in Focus Quanterix (NASDAQ:QTRX) lowered its 2026 financial outlook after second-quarter revenue failed to meet management’s expectations despite increasing 34% year…